Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Citius Pharmaceuticals, Inc. (CTXR) had Return on Tangible Equity of -21.23% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-10.92M |
|
-- |
|
-- |
|
$11.26M |
|
$-11.26M |
|
$0.01M |
|
$-11.25M |
|
$-11.25M |
|
$-11.51M |
|
$-11.51M |
|
$-11.51M |
|
$-11.51M |
|
$-11.26M |
|
$-11.20M |
|
8.58M |
|
8.58M |
|
$-1.27 |
|
$-1.27 |
|
| Balance Sheet Financials | |
$18.37M |
|
-- |
|
$103.11M |
|
$121.48M |
|
$49.88M |
|
-- |
|
$8.03M |
|
$57.91M |
|
$63.58M |
|
$54.23M |
|
$63.58M |
|
8.76M |
|
| Cash Flow Statement Financials | |
$-9.27M |
|
-- |
|
$6.04M |
|
$3.25M |
|
$0.03M |
|
$-3.23M |
|
$5.23M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.37 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.27M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-18.11% |
|
|
Return on Tangible Equity |
-21.23% |
-9.48% |
|
-18.11% |
|
$7.26 |
|
$-1.08 |
|
$-1.08 |
|